We established and validated telomere gene-related prognostic features in pancreatic cancer and confirmed the upregulation of DSG2, LDHA, and RACGAP1 expression in clinical samples, which may provide new ideas for individualized immunotherapy targeting telomere genes. This evidence concerns the gene LDHA and familial pancreatic carcinoma.